Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Capital Expenditures: 2023-2025

Historic Capital Expenditures for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $748,000.

  • Immunocore Holdings' Capital Expenditures fell 9.66% to $748,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 109.64%. This contributed to the annual value of $5.2 million for FY2024, which is 4.65% down from last year.
  • Per Immunocore Holdings' latest filing, its Capital Expenditures stood at $748,000 for Q3 2025, which was up 80.68% from $414,000 recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Capital Expenditures peaked at $3.6 million during Q4 2024, and registered a low of $212,000 during Q3 2023.
  • Its 3-year average for Capital Expenditures is $1.1 million, with a median of $748,000 in 2025.
  • Within the past 5 years, the most significant YoY rise in Immunocore Holdings' Capital Expenditures was 338.68% (2024), while the steepest drop was 85.67% (2024).
  • Immunocore Holdings' Capital Expenditures (Quarterly) stood at $817,000 in 2023, then skyrocketed by 338.68% to $3.6 million in 2024, then fell by 9.66% to $748,000 in 2025.
  • Its Capital Expenditures stands at $748,000 for Q3 2025, versus $414,000 for Q2 2025 and $298,000 for Q1 2025.